Long COVID and Cardiovascular Disease: a Prospective Cohort Study

Background: Pre-existing cardiovascular disease (CVD) or cardiovascular risk factors have been associated with an increased risk of complications following hospitalisation with COVID-19, but their impact on the rate of recovery following discharge is not known.

Objectives: To determine whether the rate of patient-perceived recovery following hospitalisation with COVID-19 was affected by the presence of CVD or cardiovascular risk factors.

Methods: In a multicentre prospective cohort study, patients were recruited following discharge from the hospital with COVID-19 undertaking two comprehensive assessments at 5 months and 12 months. Patients were stratified by the presence of either CVD or cardiovascular risk factors prior to hospitalisation with COVID-19 and compared with controls with neither. Full recovery was determined by the response to a patient-perceived evaluation of full recovery from COVID-19 in the context of physical, physiological and cognitive determinants of health.

Results: From a total population of 2545 patients (38.8% women), 472 (18.5%) and 1355 (53.2%) had CVD or cardiovascular risk factors, respectively. Compared with controls (n=718), patients with CVD and cardiovascular risk factors were older and more likely to have had severe COVID-19. Full recovery was significantly lower at 12 months in patients with CVD (adjusted OR (aOR) 0.62, 95% CI 0.43 to 0.89) and cardiovascular risk factors (aOR 0.66, 95% CI 0.50 to 0.86).

Conclusion: Patients with CVD or cardiovascular risk factors had a delayed recovery at 12 months following hospitalisation with COVID-19. Targeted interventions to reduce the impact of COVID-19 in patients with cardiovascular disease remain an unmet need.

Trail Registration Number: ISRCTN10980107.

Citing Articles

Long COVID science, research and policy.

Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A Nat Med. 2024; 30(8):2148-2164.

PMID: 39122965 DOI: 10.1038/s41591-024-03173-6.

References

Singh S, Jones P, Evans R, Morgan M . Minimum clinically important improvement for the incremental shuttle walking test. Thorax. 2008; 63(9):775-7. DOI: 10.1136/thx.2007.081208. View

Elneima O, McAuley H, Leavy O, Chalmers J, Horsley A, Ho L . Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study. Int J Epidemiol. 2024; 53(1). PMC: 10859139. DOI: 10.1093/ije/dyad165. View

Singh T, Kite T, Joshi S, Spath N, Kershaw L, Baker A . MRI and CT coronary angiography in survivors of COVID-19. Heart. 2021; 108(1):46-53. PMC: 8503921. DOI: 10.1136/heartjnl-2021-319926. View

Smeeth L, Thomas S, Hall A, Hubbard R, Farrington P, Vallance P . Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351(25):2611-8. DOI: 10.1056/NEJMoa041747. View

Hastie C, Lowe D, McAuley A, Winter A, Mills N, Black C . Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022; 13(1):5663. PMC: 9556711. DOI: 10.1038/s41467-022-33415-5. View

. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. Lancet Respir Med. 2023; 11(11):1003-1019. PMC: 7615263. DOI: 10.1016/S2213-2600(23)00262-X. View

. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. Eur Heart J. 2021; 43(11):1104-1120. DOI: 10.1093/eurheartj/ehab656. View

Brightling C, Evans R . Long COVID: which symptoms can be attributed to SARS-CoV-2 infection?. Lancet. 2022; 400(10350):411-413. PMC: 9352303. DOI: 10.1016/S0140-6736(22)01385-X. View

Nguyen J, Yang W, Ito K, Matte T, Shaman J, Kinney P . Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016; 1(3):274-81. PMC: 5158013. DOI: 10.1001/jamacardio.2016.0433. View

10.

Dharmarajan K, Hsieh A, Kulkarni V, Lin Z, Ross J, Horwitz L . Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ. 2015; 350:h411. PMC: 4353309. DOI: 10.1136/bmj.h411. View

11.

Lundberg-Morris L, Leach S, Xu Y, Martikainen J, Santosa A, Gisslen M . Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ. 2023; 383:e076990. PMC: 10666099. DOI: 10.1136/bmj-2023-076990. View

12.

McAuley H, Evans R, Bolton C, Brightling C, Chalmers J, Docherty A . Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. EClinicalMedicine. 2023; 57:101896. PMC: 10005893. DOI: 10.1016/j.eclinm.2023.101896. View

13.

Bramante C, Huling J, Tignanelli C, Buse J, Liebovitz D, Nicklas J . Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022; 387(7):599-610. PMC: 9945922. DOI: 10.1056/NEJMoa2201662. View

14.

Finnigan L, Cassar M, Koziel M, Pradines J, Lamlum H, Azer K . Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study. EClinicalMedicine. 2023; 59:101946. PMC: 10102537. DOI: 10.1016/j.eclinm.2023.101946. View

15.

Evans R, McAuley H, Harrison E, Shikotra A, Singapuri A, Sereno M . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021; 9(11):1275-1287. PMC: 8497028. DOI: 10.1016/S2213-2600(21)00383-0. View

16.

Ballering A, van Zon S, Olde Hartman T, Rosmalen J . Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022; 400(10350):452-461. PMC: 9352274. DOI: 10.1016/S0140-6736(22)01214-4. View

17.

Alotaibi J, Doherty P . Evaluation of determinants of walking fitness in patients attending cardiac rehabilitation. BMJ Open Sport Exerc Med. 2017; 2(1):e000203. PMC: 5569262. DOI: 10.1136/bmjsem-2016-000203. View

18.

Frobert O, Gotberg M, Erlinge D, Akhtar Z, Christiansen E, MacIntyre C . Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021; 144(18):1476-1484. DOI: 10.1161/CIRCULATIONAHA.121.057042. View

19.

Artico J, Shiwani H, Moon J, Gorecka M, McCann G, Roditi G . Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study. Circulation. 2023; 147(5):364-374. PMC: 9889203. DOI: 10.1161/CIRCULATIONAHA.122.060632. View

20.

Sipila P, Lindbohm J, Batty G, Heikkila N, Vahtera J, Suominen S . Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study. Circulation. 2023; 147(21):1582-1593. DOI: 10.1161/CIRCULATIONAHA.122.061183. View